What Happened

Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG), enrolling ~195 AChR+ patients. The study evaluates subcutaneous dosing every 2 or 4 weeks versus placebo, with primary data expected 2H 2028.

Who Is Affected

Neuromuscular disease specialists, autoimmune researchers, and biopharma partners focused on gMG, CIDP, or MMN. Dianthus' R&D team emphasized strong investigator interest globally following positive Phase 2 MaGic trial results.

Market Impact

• DNTH stock historically moves ~7.5% on clinical trial announcements
• $600M shelf offering provides financing flexibility but dilution risk
• Sector-wide biotech bid observed (ELVN, ZYME, AMLX, NTLA up)

What to Watch

Monitor enrollment pace for this global multicenter trial and any pipeline expansions into MMN/CIDP. The 2028 timeline creates a long validation window for competitors or partners.